Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

BriaCell receives FDA approval to begin phase I/IIa trial of BriaVax

Nov. 5, 2015

Innate initiates phase I study of IPH-4102 in CTCL

Nov. 5, 2015

Launch of managed access program for Unituxin

Nov. 4, 2015

Merck & Co. receives FDA breakthrough therapy designation for Keytruda in colorectal cancer

Nov. 3, 2015

OncoSec Medical starts biomarker study of ImmunoPulse IL-12 in triple-negative breast cancer

Nov. 2, 2015

Igenica Biotherapeutics begins strategic oncology research agreement with MedImmune

Oct. 30, 2015

FDA approves Yervoy for adjuvant treatment of fully resected stage III melanoma

Oct. 29, 2015

KaloBios starts phase I trial of KB-003 in patients with CMML

Oct. 29, 2015

FDA approves Imlygic as first oncolytic viral therapy in U.S.

Oct. 28, 2015

Pembrolizumab superior to docetaxel in overall survival of patients with advanced NSCLC

Oct. 27, 2015

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...